Hyderabad, 5 June 2024: The 10th edition of PharmaLytica, organised by Informa Markets in India, concluded successfully at HITEX, Hyderabad. The event focused on redefining the pharmaceutical industry in the post-COVID era.

PharmaLytica 2024 offered a unique platform for stakeholders to engage in discussions covering the full spectrum of pharma machinery and packaging, lab analytical and cleanroom solutions, and pharmaceutical ingredients. This year’s edition saw participation from over 5,000 visitors and more than 200 exhibitors showcasing 1000+ brands. They reaffirmed the need and focus of PharmaLytica as an industry event to boost and facilitate the pharmaceutical sector.

Key exhibitors included Hetero, Emvee Engineers, Schneider Electric, Integrated Cleanroom Technology, Nicomac Taikisha Clean Rooms, HLE Glascoat Ltd, Scientific Research Instruments Company, Ami Polymer, and many more. Industry associations such as BDMAI (Bulk Drug Manufacturers Association (India)), FOPE (Federation of Pharma Entrepreneurs), and IPC (Indian Pharmacopoeia Commission) primarily supported the expos. Additionally, Telangana Life Sciences served as a supporting partner, while ETRIC was the e-mobility partner for the event.

The special inauguration ceremony of the trade expo was marked by the presence of key dignitaries, such as Shri Udaya Bhaskar, Director General, Pharmexcil, and Shri AVPS Chakravarthi, Ambassador—World Packaging Organisation.

& Board Member, Pharmexcil; Orhan Yalman Okan, The Consul General, Consulate General of Turkey; Mr. Yogesh Mudras, Managing Director of Informa Markets in India; and Mr. Rahul Deshpande, Senior Group Director, Informa Markets in India.

Highlighting the significant growth of the Pharmaceutical Industry, Shri Udaya Bhaskar, Director General of the Pharmaceuticals Export Promotion Council of India (Pharmexcil), said, “During the pandemic and post-pandemic period, the Indian pharmaceutical industry made significant contributions. We exported USD 27.8 billion worth of drugs in the financial year 2024, achieving a 9.6% growth rate despite numerous global challenges. We expect to reach over USD 31 billion in the next financial year. 50% of our exports are going to highly regulated markets. In North America and Europe, it’s almost 55%. In the US, we exported more than 8 billion with a 15% growth rate; in the UK, we achieved a 21% growth rate. This demonstrates the robust growth of the Indian pharmaceutical industry, even in challenging situations. The industry will remain unmatched if India continues to manufacture quality drugs at affordable prices.”

Emphasizing the potential of pharma trade between India and Turkey, The Consul General Consulate General of Turkey, Mr. Orhan Yalman Okan, said, “Hyderabad is becoming a global city, particularly in the pharma sector, making it the pharma capital of India. India and Turkey are rising in this field, presenting significant trade and cooperation opportunities In 2022, the global pharmaceutical market reached a value of USD 1.5 trillion, with Turkey ranking 21st. The Turkish pharmaceutical market grew by an impressive 80%, reaching around USD 38 billion and unit sales hitting USD 2.8 billion. The industry employs over 45,000 staff and offers over 12,000 products. Turkey’s pharmaceutical exports were USD 2.2 billion, reaching over 170 countries. The medical devices market was USD 2.9 billion, and medical tourism contributed USD 2.5 billion. PharmaLytica 2024 aims to foster deeper understanding and cooperation within the pharmaceutical domain. By sharing pertinent insights into Turkey’s pharmaceutical landscape, including its remarkable growth trajectory, regulatory framework, and export prowess, we aim to cultivate a clearer understanding of the sector’s potential.”

Shri. AVPS Chakravarthi, Ambassador, World Packaging Organisation & Board Member Pharmexcil, said, “Pharmalytica has grown into a permanent landmark of innovation in the pharmaceutical industry from Mumbai to Bangalore and now Hyderabad. There’s no room for compromise on quality in life-saving and life-sustaining industries. Our exports to highly regulated markets like the USA, where over 50% of our products are consumed, reflect our uncompromising standards. The collaboration between India and US authorities aims to ensure the availability of safe, high-quality drugs. Hyderabad, often called the second Silicon Valley of the world, integrates digital and chemical technologies, making it a hub for pharmaceutical innovation. The city hosts more than 214 USFDA-approved facilities, accounting for over 35% of India’s pharmaceutical production. Additionally, Hyderabad is a significant center for medical devices and packaging, having become self-sufficient even during the COVID-19 supply chain challenges.”

Speaking on the sidelines of the inaugural, Dr. Gaurav Pratap Singh, Senior Principal Scientific Officer, Indian Pharmacopoeia Commission, said, “India’s reputation as the ‘Pharmacy of the World’ is well-earned, with our commitment to supplying high-quality and affordable medicines globally. Our leadership in vaccine supply to WHO, coupled with meeting the generics demands of the USA, Britain, and Europe, underscores our pivotal role in healthcare accessibility. The significant growth in biosimilar approvals and manufacturing further enhances patient access to biopharmaceuticals. With strategic investments in developing generic and biopharmaceutical versions, India stands poised to maintain its global pharmaceutical leadership. Innovation remains paramount, especially in emerging prophylactic and therapeutic products like medical devices, complex generics, monoclonal antibodies, and gene therapy. Setting robust regulations for their development and marketing is crucial for sustained growth. While quality concerns highlighted by WHO and other regulatory agencies necessitate stringent quality control measures, platforms like PharmaLytica 2024 play a vital role in prioritizing quality in the pharmaceutical sector. Looking ahead, there’s immense potential to replicate the success of hubs like Hyderabad and Bengaluru in Tamil Nadu and Kerala, creating new avenues for growth in the pharma industry.”

Addressing the opportunities in this sector, Mr. Yogesh Mudras, Managing Director of Informa Markets in India, said, “In 2024, the Indian pharmaceutical industry remains a global leader across the entire supply chain. It ranks third in production by volume and in terms of Active Pharmaceutical Ingredients (APIs) globally. With over 500 different APIs manufactured domestically, India contributes 57% of APIs to the WHO’s prequalified list. The medical devices sector in India stands at a market size of US$ 11 billion. By 2032, the India analytical laboratory instruments market is projected to hit $4142.85 million, propelled by the government’s focus on boosting production, notably supported by the flourishing pharmaceutical sector.

Situated in Hyderabad, the epicentre of India’s bulk drug production, and nestled within South India’s mature pharma ecosystem, Pharmalytica emerges as a vital regional hub for industry leaders and stakeholders with discussions surrounding emerging trends, prevalent challenges, and promising opportunities,” he added.